ES2435403T3 - Tratamiento de trastornos del sueño y vigilia - Google Patents

Tratamiento de trastornos del sueño y vigilia Download PDF

Info

Publication number
ES2435403T3
ES2435403T3 ES06772647T ES06772647T ES2435403T3 ES 2435403 T3 ES2435403 T3 ES 2435403T3 ES 06772647 T ES06772647 T ES 06772647T ES 06772647 T ES06772647 T ES 06772647T ES 2435403 T3 ES2435403 T3 ES 2435403T3
Authority
ES
Spain
Prior art keywords
enantiomer
formula
group
use according
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06772647T
Other languages
English (en)
Spanish (es)
Inventor
Abdallah Ahnaou
Wilhelmus H.I.M Drinkenburg
Joseph Palumbo
Jonathan Sporn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2435403(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2435403T3 publication Critical patent/ES2435403T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES06772647T 2005-06-08 2006-06-07 Tratamiento de trastornos del sueño y vigilia Active ES2435403T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
US688638P 2005-06-08
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (1)

Publication Number Publication Date
ES2435403T3 true ES2435403T3 (es) 2013-12-19

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06772647T Active ES2435403T3 (es) 2005-06-08 2006-06-07 Tratamiento de trastornos del sueño y vigilia

Country Status (17)

Country Link
US (8) US8440715B2 (enExample)
EP (1) EP1890684B1 (enExample)
JP (1) JP5024635B2 (enExample)
KR (1) KR101335941B1 (enExample)
CN (1) CN101217949B (enExample)
AU (1) AU2006254899B2 (enExample)
BE (1) BE2020C004I2 (enExample)
BR (1) BRPI0613697A2 (enExample)
CA (1) CA2611713C (enExample)
DK (1) DK1890684T3 (enExample)
ES (1) ES2435403T3 (enExample)
FR (1) FR20C1014I2 (enExample)
NL (1) NL301037I2 (enExample)
PL (1) PL1890684T3 (enExample)
RU (1) RU2417077C2 (enExample)
TW (2) TW201328689A (enExample)
WO (1) WO2006133393A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
WO2007001841A1 (en) * 2005-06-22 2007-01-04 Sk Holdings Co., Ltd. Treatment of sexual dysfunction
KR102021075B1 (ko) 2009-06-22 2019-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(adhd)의 치료 방법
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
HRP20221018T1 (hr) * 2013-03-13 2023-01-06 Jazz Pharmaceuticals Ireland Limited Liječenje katapleksije
ES2812586T3 (es) 2013-07-18 2021-03-17 Jazz Pharmaceuticals Ireland Ltd Tratamiento para la obesidad
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
WO2016061488A1 (en) * 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥/多動性障害(adhd)の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
CN109996540A (zh) 2016-09-06 2019-07-09 爵士制药国际Iii有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯的溶剂化物形式
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2964943T3 (es) 2016-10-06 2024-04-10 Axsome Malta Ltd Compuestos de carbamoilfenilalaninol para uso médico
MY203401A (en) 2017-06-02 2024-06-26 Jazz Pharmaceuticals Ireland Ltd Methods and compositions for treating excessive sleepiness
US11413264B2 (en) * 2017-07-31 2022-08-16 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
AU2023375326A1 (en) * 2022-11-07 2025-05-22 Axsome Therapeutics Compositions and methods for treating insomnia
EP4626417A1 (en) * 2022-11-30 2025-10-08 Axsome Therapeutics Methods and compositions for improving driving performance
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) * 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
CA2439286A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating anxiety disorders
WO2002067926A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
WO2002067921A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
AU2005302589B2 (en) 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
WO2007001841A1 (en) 2005-06-22 2007-01-04 Sk Holdings Co., Ltd. Treatment of sexual dysfunction
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
EA200970377A1 (ru) 2006-10-13 2009-10-30 Янссен Фармацевтика Нв Композиции фенилалкиламинокарбамата
KR102021075B1 (ko) 2009-06-22 2019-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(adhd)의 치료 방법
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
HRP20221018T1 (hr) * 2013-03-13 2023-01-06 Jazz Pharmaceuticals Ireland Limited Liječenje katapleksije

Also Published As

Publication number Publication date
US20140350098A1 (en) 2014-11-27
BE2020C004I2 (enExample) 2026-01-06
US20240239740A1 (en) 2024-07-18
DK1890684T3 (da) 2013-10-14
CA2611713C (en) 2013-10-01
US20210078943A1 (en) 2021-03-18
JP2008545795A (ja) 2008-12-18
NL301037I2 (nl) 2020-05-12
US10351517B2 (en) 2019-07-16
BRPI0613697A2 (pt) 2011-01-25
US8440715B2 (en) 2013-05-14
CN101217949B (zh) 2012-10-17
FR20C1014I2 (fr) 2021-04-23
KR101335941B1 (ko) 2013-12-04
TWI419681B (zh) 2013-12-21
JP5024635B2 (ja) 2012-09-12
WO2006133393A1 (en) 2006-12-14
US9604917B2 (en) 2017-03-28
RU2417077C2 (ru) 2011-04-27
US20090312416A1 (en) 2009-12-17
FR20C1014I1 (enExample) 2020-06-12
PL1890684T3 (pl) 2014-05-30
US20170158622A1 (en) 2017-06-08
US12209059B2 (en) 2025-01-28
US20250109099A1 (en) 2025-04-03
US20130137764A1 (en) 2013-05-30
EP1890684A1 (en) 2008-02-27
TW200716084A (en) 2007-05-01
TW201328689A (zh) 2013-07-16
EP1890684B1 (en) 2013-08-14
US8877806B2 (en) 2014-11-04
RU2008100019A (ru) 2009-07-20
US20190367448A1 (en) 2019-12-05
US11753368B2 (en) 2023-09-12
AU2006254899A1 (en) 2006-12-14
KR20080035565A (ko) 2008-04-23
AU2006254899B2 (en) 2011-11-24
CA2611713A1 (en) 2006-12-14
NL301037I1 (enExample) 2020-04-01
CN101217949A (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
ES2435403T3 (es) Tratamiento de trastornos del sueño y vigilia
ES2743153T3 (es) Métodos para tratar el síndrome de fibromialgia
ES2638074T3 (es) Carbamatos para utilizar en el síndrome de piernas inquietas
US8093262B2 (en) Use of huperzine for disorders
CA2416819C (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
US7087643B2 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
MXPA04000555A (es) Compuestos de carbamato para utilizarse en la prevencion o tratamiento del dolor neuropatico y el dolor asociado con la cefalea acuminada y migranosa.
AU2002322442A1 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain